Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.88 |
| ▸ | NR5A2 | O00482 | 1/20 | 0.88 |
| ▸ | NR5A1 | Q13285 | 1/20 | 0.88 |
| ▸ | MAPT | P10636 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.78 |
| ▸ | FABP3 | P05413 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.59 |
| ▸ | PTAFR | P25105 | 1/20 | 0.59 |
| ▸ | HTR1D | P28221 | 1/20 | 0.59 |
| ▸ | HTR2C | P28335 | 1/20 | 0.59 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.58 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.58 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.58 |
| ▸ | PRKCA | P17252 | 1/20 | 0.58 |
| ▸ | SELP | P16109 | 1/20 | 0.57 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL159882 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL15709161 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL178155 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL234634 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL23188433 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL235532 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL25354838 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL45162 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL22492184 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 | |
| SCHEMBL1649042 | 1.00 | SMN1; SMN2 (0.88) | SMN1; SMN2NR5A2NR5A1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743094-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | Eden Ophthalmic Pte Ltd. (SG) | 2026-05-20 | — | — | EP | claimed |
| WO-2025015046-A1 | LIPOSOMAL FORMULATIONS OF CORTICOSTEROIDS AND USES THEREOF | EDEN OPHTHALMIC PTE LTD. (SG) | 2025-01-16 | — | — | WO | claimed |
| EP-4482511-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | The Regents of The University of Michigan (US) | 2025-01-01 | — | — | EP | claimed |
| WO-2023164476-A2 | COMPOSITIONS AND METHODS FOR TREATING AUTOIMMUNE DISORDERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2023-08-31 | — | — | WO | claimed |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | CODIAK BIOSCIENCES, INC. (US) | 2022-11-10 | — | — | US | claimed |
| EP-2444464-A1 | Novel neutral (bio)material | Centre National de la Recherche Scientifique (CNRS) (FR) | 2012-04-25 | — | — | EP | claimed |
| US-20080118489-A1 | Charge-Modified Lysozyme Antimicrobial Compositions, Surfactants, and Methods for Infections and Cystic Fibrosis | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-05-22 | — | — | US | claimed |
| EP-4731266-A1 | NANOPARTICLE COMPOSITIONS ASSOCIATED WITH PEPTIDES | The Regents of the University of Michigan (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4637812-A1 | HEPATITIS B COMPOSITIONS | GlaxoSmithKline Biologicals S.A. (BE) | 2025-10-29 | — | — | EP | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| WO-2025133951-A1 | IONIZABLE LIPIDS SUITABLE FOR LIPID NANOPARTICLES | GENEVANT SCIENCES GMBH (CH) | 2025-06-26 | — | — | WO | disclosed |
| EP-4539876-A2 | RECOMBINANT RNA MOLECULES COMPRISING UNTRANSLATED REGIONS OR SEGMENTS ENCODING SPIKE PROTEIN FROM THE OMICRON STRAIN OF SEVERE ACUTE RESPIRATORY CORONAVIRUS-2 | GlaxoSmithKline Biologicals S.A. (BE) | 2025-04-23 | — | — | EP | disclosed |
| EP-4522646-A2 | APOE LIPOPROTEIN SYSTEMS | Kisbee Therapeutics, Inc. (US) | 2025-03-19 | — | — | EP | disclosed |
| WO-2010053489-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2081552-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | Children's Hospital Medical Center (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20090142267-A1 | FUSOGENIC PROPERTIES OF SAPOSIN C AND RELATED PROTEINS AND PEPTIDES FOR APPLICATION TO TANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER | 2009-06-04 | — | — | US | disclosed |
| EP-2020988-A2 | COMPOSITIONS COMPRISING FUSOGENIC PROTEINS OR POLYPEPTIDES DERIVED FROM PROSAPOSIN FOR APPLICATION IN TRANSMEMBRANE DRUG DELIVERY SYSTEMS | Children's Hospital Medical Center (US) | 2009-02-11 | — | — | EP | disclosed |
| US-20080118489-A1 | Charge-Modified Lysozyme Antimicrobial Compositions, Surfactants, and Methods for Infections and Cystic Fibrosis | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008051818-A2 | SPONTANEOUSLY FORMING ELLIPSOIDAL PHOSPHOLIPID UNILAMELLAR VESICLES | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2007127439-A2 | COMPOSITIONS COMPRISING FUSOGENIC PROTEINS OR POLYPEPTIDES DERIVED FROM PROSAPOSIN FOR APPLICATION IN TRANSMEMBRANE DRUG DELIVERY SYSTEMS | CHILDREN'S HOSPITAL MEDICAL CENTER (US) | 2007-11-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | SMN1; SMN2 1150/4885NR5A2 2095/4885NR5A1 3094/4885 |
| US-20220354963-A1 | EXTRACELLULAR VESICLE LINKED TO MOLECULES AND USES THEREOF | EXOSC5, EXOSC4, EXOSC10 | SMN1; SMN2 1847/4885NR5A2 4354/4885NR5A1 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.